OrsoBio To Advance TLC-6740 After Successful Obesity Combo Trial

 
• By Alaric DeArment
  
OrsoBio announced Phase Ib/IIa topline data for TLC-6740 combined with Eli Lilly's tirzepatide. (Shutterstock)

More from Musculoskeletal

More from Therapy Areas